Leading the Way in Life Science Technologies

GEN Exclusives

More »

April 15, Vol. 32, No. 8

  • Feature Articles

    • Redefining Oligonucleotide Production
    • Neil McKenna, Ph.D.
    • Oligonucleotide therapeutics make up a small but rapidly growing segment of the overall global drug pipeline, with 245 programs currently in development today While only one approved oligo therapeutic is currently on the market (Pfizer’s Macugen®), there are currently nearly ... more »
    • Bringing GPCR Research to the Fore
    • Michael D. O'Neil
    • The group of seven transmembrane-spanning G protein-coupled receptors (GPCRs) represents the largest superfamily of receptors in the human genome GPCRs are involved in virtually all physiological processes and represent the targets for at least 30% of all current medicines GPCRs ... more »
    • Cracking the PTM Code
    • David Daniels, Ph.D.
    • Post-translational modifications contribute to the structure, function, and efficacy of the therapeutic antibody The extent to which the antibody is modified and the location of the modifications all contribute to the overall effectiveness of the biotherapeutic What we are learning ... more »
    • Single-Use Systems Drive Down Costs
    • Sue Pearson, Ph.D.
    • The world’s population is getting older and is requiring more effective, often biological-based treatments for endemic diseases such as diabetes and rheumatoid arthritis “In emerging markets, governments are looking to vaccinate or treat diseases in larger numbers of their population ... more »